EAU 2026: Optimizing Germline & Somatic Testing for Prostate Cancer

EAU 2026: Optimizing Germline & Somatic Testing for Prostate Cancer

March 16, 2026 Nkechi Okonkwo- Health Editor Health

The evolving landscape of prostate cancer care is increasingly informed by genetic testing and recent discussions at the European Association of Urology (EAU) 2026 congress focused on optimizing both germline and somatic testing strategies. This shift reflects a growing understanding of the role genetics play in both prostate cancer development and treatment response. Understanding these tests, and how they’re used, is becoming central to personalized care for men facing this diagnosis.

What are Germline and Somatic Tests?

To understand the optimization strategies discussed at EAU 2026, it’s helpful to define the two types of genetic testing involved. Germline testing examines a person’s healthy cells for genetic changes inherited from their parents. These inherited changes can increase a person’s overall risk of developing certain cancers, including prostate cancer. Somatic testing, analyzes the DNA within the tumor cells themselves, looking for genetic alterations that have occurred during the cancer’s development. These alterations aren’t inherited; they arise spontaneously within the tumor and can influence how the cancer grows and responds to treatment.

Both types of testing are becoming increasingly important, particularly for men with advanced or recurrent prostate cancer. As the Prostate Cancer Foundation explains, getting both tests provides the most complete picture for doctors and patients when making treatment decisions.

The Rising Importance of Germline Testing

Germline testing for prostate cancer is no longer a niche practice. Recent data, highlighted at EAU 2026, demonstrates its central role in both prostate cancer care and broader hereditary cancer risk assessment. Research published in May 2025 indicates a rising role for germline testing not only in diagnosis but also in screening strategies. This is particularly relevant for men with a family history of prostate cancer or other related cancers, such as breast or ovarian cancer.

Currently, germline testing is considered standard of care for patients with metastatic, recurrent, or high-risk prostate cancer, according to findings presented at EAU 2026. This means that these patients should be offered germline testing as part of their routine care. The goal is to identify genetic mutations – like those in the BRCA1/2 genes – that may influence treatment choices, such as the employ of PARP inhibitors, or indicate a need for family member screening.

Optimizing Testing Strategies: What Was Discussed at EAU 2026?

The focus at EAU 2026 wasn’t simply on *whether* to test, but *how* to test most effectively. Several key areas were addressed:

  • Expanding Access: Ensuring equitable access to genetic testing remains a challenge. Discussions centered on strategies to overcome barriers to testing, particularly in underserved populations.
  • Interpreting Results: Genetic testing reports can be complex. EAU 2026 sessions emphasized the need for clear communication between genetic counselors, oncologists, and patients to ensure that results are understood and appropriately acted upon.
  • Integrating Results into Clinical Practice: The availability of genetic information requires a shift in clinical workflows. Presentations explored how to best integrate genetic testing results into treatment planning and follow-up care.
  • Multi-Gene Panels vs. Targeted Testing: There’s ongoing debate about whether to use broad multi-gene panels or focus on testing for specific, well-established cancer-associated genes. The consensus at EAU 2026 leaned towards a more targeted approach, at least initially, to minimize the detection of variants of uncertain significance (VUS).

Somatic Testing: Guiding Treatment Decisions

Even as germline testing provides insight into inherited risk, somatic testing focuses on the unique genetic characteristics of the tumor itself. This information can be crucial for selecting targeted therapies. For example, identifying specific mutations in genes like TP53 or PIK3CA can help predict which treatments are most likely to be effective.

The combination of germline and somatic testing allows for a more personalized approach to prostate cancer treatment. A man’s inherited genetic predisposition, combined with the specific genetic profile of his tumor, can guide treatment decisions and improve outcomes.

What Does This Mean for Patients?

The advancements discussed at EAU 2026 offer hope for more effective and personalized prostate cancer care. If you have been diagnosed with prostate cancer, particularly advanced or recurrent disease, it’s important to discuss genetic testing with your doctor. Understanding your genetic profile can help you and your care team craft informed decisions about your treatment plan.

It’s also important to remember that genetic testing is not a one-time event. As our understanding of cancer genetics evolves, novel tests and interpretations may develop into available. Regular follow-up with a genetic counselor or oncologist is essential to stay informed about the latest advancements.

Looking Ahead: The Future of Genetic Testing in Prostate Cancer

The field of cancer genetics is rapidly evolving. Ongoing research is focused on identifying new genetic markers that can predict treatment response and disease progression. Clinical trials are also underway to evaluate the effectiveness of new targeted therapies based on genetic testing results.

The implementation of germline testing, as highlighted at EAU 2026, requires ongoing efforts to refine testing protocols, improve data interpretation, and ensure equitable access for all patients. Continued research and collaboration will be essential to unlock the full potential of genetic testing in the fight against prostate cancer.